Duloxetine

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Atypical Depression

Conditions

Atypical Depression

Trial Timeline

Mar 1, 2005 → —

NCT ID

NCT00296699

About Duloxetine

Duloxetine is a approved stage product being developed by Eli Lilly for Atypical Depression. The current trial status is completed. This product is registered under clinical trial identifier NCT00296699. Target conditions include Atypical Depression.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01391221	Approved	UNKNOWN	Jul 1, 2011	Aug 1, 2013	Major Depression
NCT01363284	Pre-clinical	Completed	Jun 1, 2010	Aug 1, 2012	Diabetes
NCT01089621	Approved	Withdrawn	Mar 1, 2010	Aug 1, 2010	Fibromyalgia
NCT01051466	Approved	Completed	Jan 1, 2010	Mar 1, 2013	Major Depressive Disorder
NCT00989157	Phase 3	Completed	Sep 1, 2009	Nov 1, 2012	Bariatric Surgery
NCT01074151	Pre-clinical	Completed	Jul 1, 2009	Jul 26, 2021	Pregnancy
NCT00889369	Approved	UNKNOWN	May 1, 2009	Jun 1, 2012	Major Depressive Disorder
NCT01754493	Approved	Completed	Dec 1, 2008	Dec 1, 2014	Major Depression
NCT01028352	Pre-clinical	Completed	Oct 1, 2008	Oct 1, 2011	Breast Cancer
NCT00696774	Approved	Completed	Jun 1, 2008	Jul 1, 2009	Depressive Disorder, Major
NCT00532480	Approved	Completed	Sep 1, 2007	Apr 1, 2009	Major Depression
NCT00529789	Phase 2	Completed	Aug 1, 2007	Sep 1, 2008	Major Depressive Disorder
NCT00696293	Approved	Completed	May 1, 2007	Apr 1, 2010	Major Depressive Disorder
NCT00517985	Approved	Completed	Feb 1, 2007	Jun 1, 2008	Major Depressive Disorder
NCT00398632	Approved	Terminated	Nov 1, 2006	Apr 1, 2009	Depression
NCT00401258	Approved	Completed	Nov 1, 2006	Feb 1, 2008	Irritable Bowel Syndrome
NCT00438971	Approved	Completed	Aug 1, 2006	Jan 1, 2009	Panic Disorder
NCT00531895	Approved	Completed	Apr 1, 2006	Mar 1, 2007	Major Depression
NCT00322621	Approved	Completed	Apr 1, 2006	Oct 1, 2007	Diabetic Neuropathies
NCT01035073	Approved	Completed	Apr 1, 2006	May 1, 2009	Major Depressive Disorder

Competing Products

18 competing products in Atypical Depression

See all competitors

Product	Company	Stage	Hype Score
Crovalimab	Chugai Pharmaceutical	Phase 3	77
Crovalimab	Chugai Pharmaceutical	Phase 3	77
Teriparatide 20 mcg	Eli Lilly	Phase 3	77
Baricitinib	Eli Lilly	Pre-clinical	23
Ravulizumab	AstraZeneca	Pre-clinical	23
Eculizumab	AstraZeneca	Phase 3	77
Iptacopan	Novartis	Phase 3	77
Iptcaopan 200 mg	Novartis	Phase 3	77
Iptacopan	Novartis	Phase 3	77
Ropeginterferon Alfa-2B	PharmaEssentia	Phase 2	51
CCX168	Amgen	Phase 2	51
Tazemetostat + Nivolumab + Ipilimumab	Bristol Myers Squibb	Phase 1/2	40
Cemdisiran	Alnylam Pharmaceuticals	Phase 2	49
cemdisiran + Placebos	Alnylam Pharmaceuticals	Phase 2	49
Axatilimab + Azacitidine	Incyte	Phase 1/2	38
Gemcitabine + Paxalisib	Pacific Biosciences	Phase 2	44
Apatinib Mesylate	Brain Biotech	Pre-clinical	15
azurin-derived cell-penetrating peptide p28	Brain Biotech	Phase 1	25

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved